Hypothesis

Humanin and other mitochondrial-derived peptides (MDPs) act as molecular switches that preferentially engage receptor-mediated mitophagy (BNIP3L/NIX, FUNDC1) while suppressing the PINK1-Parkin damage-sensing axis, thereby determining which mitochondrial subpopulations are retained during cellular stress.

Mechanistic Rationale

Recent work shows that in cardiac progenitor cells mitophagy is driven chiefly by BNIP3L/NIX and FUNDC1, targeting non-depolarized mitochondria for preemptive remodeling [1]. Humanin is known to promote survival via FPRL1/2 and CNTFR/gp130 receptors, inhibiting Bax/tBid and activating downstream signaling cascades [2]. We propose that Humanin-bound FPRL1 triggers a Gαi‑mediated reduction in cAMP, activating protein kinase A (PKA) which phosphorylates Drp1 at the inhibitory Ser637 site. Concurrently, Humanin may expose a cryptic LC3-interacting region (LIR) within its sequence, allowing direct interaction with LC3 on mitochondria earmarked for BNIP3L/NIX or FUNDC1 recruitment. This dual action would (1) curb excessive fission driven by Drp1-Ser616 phosphorylation and (2) scaffold autophagosome formation preferentially at receptor-rich mitochondrial domains, shifting the mitophagy hierarchy toward programmed remodeling rather than damage‑induced clearance.

Testable Predictions

1. Overexpression of Humanin in cardiac progenitor cells will increase mt‑Keima flux that is sensitive to BNIP3L/NIX or FUNDC1 knockdown but resistant to PINK1 or Parkin loss.
2. Humanin treatment will reduce phospho‑Drp1‑Ser616 levels and increase phospho‑Drp1‑Ser637, an effect blocked by FPRL1 antagonism or PKA inhibition.
3. Synthetic Humanin peptides containing the predicted LIR motif will co‑immunoprecipitate with LC3, whereas scrambling the motif abolishes this interaction and fails to shift mitophagy flux.
4. In aged mice, circulating Humanin decline will correlate with a measurable increase in PINK1‑Parkin‑dependent mitophagy markers (e.g., ubiquitin‑positive mitochondria) in cardiac tissue, reversible by chronic Humanin supplementation.

Potential Experiments

• Treat cultured cardiac progenitors with Humanin (± FPRL1 antagonist) and measure mitophagy flux using mt‑Keima, alongside Western blots for phospho‑Drp1 (Ser616/Ser637) and LC3‑II.
• Perform CRISPR‑mediated knockout of BNIP3L/NIX or FUNDC1 and assess whether Humanin’s protective effect on respiration is lost.
• Use proximity ligation assay to detect Humanin‑LC3 contacts on mitochondria under basal and stress conditions.
• Administer Humanin via osmotic pump to aged mice, then isolate cardiac mitochondria to quantify ubiquitin‑positive versus receptor‑positive mitophagy via immunoblotting and electron microscopy.

If these predictions hold, Humanin would be revealed as a regulator that imposes a selective hierarchy on mitochondrial cannibalism, linking its age‑related decline to a shift from quality‑controlled remodeling to indiscriminate damage‑driven clearance—a mechanistic bridge between mitochondrial signaling and aging phenotypes.